From here:
Ambit Biosciences, a private biopharmaceutical company, and Israel based Teva Pharmaceutical Industries Limited, have received Investigational New Drug application (IND) clearance from the US Food and Drug Administration (FDA) for CEP-32496, a novel BRAF (V600E) kinase inhibitor.
The IND filing was based upon promising therapeutic potential for this agent, as evidenced by data revealed in recent publications in the Journal of Medicinal Chemistry and Molecular Cancer Therapeutics characterizing the preclinical properties of CEP-32496. The two publications feature results that demonstrate CEP-32496 is a selective and potent inhibitor of BRAF (V600E) in cells.
The published preclinical findings also demonstrate that CEP-32496 possesses potent and sustained anti-tumour activity in xenograft models of melanoma and colon carcinoma. CEP-32496 possesses attractive pharmacokinetic properties upon oral administration and benchmarks favourably with respect to other kinase inhibitors that have activity at the BRAF (V600E) mutated kinase.
“The data that we have generated to date in these preclinical studies lead us to believe that we have a promising drug candidate with CEP-32496 and is further validation of our successful drug discovery collaboration with Ambit,” said Bruce Ruggeri, PhD, senior director, Oncology and Inflammation Discovery Research of Teva. “We look forward to exploring the full potential of this drug candidate to improve outcomes in patients with tumors possessing the BRAF(V600E) mutation.”
Well, I am really glad that we found extremely promising drug candidate and hopefully will be able to cure different types of cancer in the nearest future! But a couple questions bothering me:
- What's wrong with other targets inhibitors? I mean CEP-32496 is not the first kinase inhibitor, why the other inhibitors do not cure the cancer?
- Why CEP-32496 should be much better or more promising than other inhibitors?
Just another inhibitor for just another kinase?
Previous "magic cure" described here.
No comments:
Post a Comment